China Resources Pharmaceutical Group Dividend yield

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
   HKD per share 
 Price  12.56
 Dividend  0.11
 Earnings  0.59
 Cash-flow  0.50
 Book value  6.61
 Equity  6.34

China Resources Pharmaceutical Group is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. China Resources Pharmaceutical Group is a company from China, and his stocks are publicly traded.

China Resources Pharmaceutical Group paid a total dividend of 691 million HKD last year, for a market value of 78,940 millions (Market Cap 20,788 millions). Dividend per share of China Resources Pharmaceutical Group is 0.11 HKD, and his stock market price 12.56 HKD.

According to the chart below, where dividend yield is displayed, China Resources Pharmaceutical Group has a dividend yield of 0.88%, lower than the amount offered by both the market average and companies from China. It is also lower than average of Health Care industry. This low dividend yield might has several explanations: company overpriced, expanding their business,...

In addition, you should compare China Resources Pharmaceutical Group dividend yield with other Pharmaceuticals and Biotechnology companies or firms from China.

Dividend yield of China Resources Pharmaceutical Group

China Resources Pharmaceutical Group Dividend Payout

About the ability of China Resources Pharmaceutical Group to maintain his current dividend of HKD 0.11 per share, an amount that accounts for 0.88%, we should study its payout ratio both on earnings and on cash-flows (see chart below). China Resources Pharmaceutical Group payout on ernings is currently 18.64%, which is lower than the market average and companies of Health Care industry, which are 38.54% and 25.72% respectively. Both figures lead us to believe that there is confidence that China Resources Pharmaceutical Groupcan maintain his current dividend.

The payout on earnings should be complemented with the payout on cash flow since it is this last amount the one which can be distributed to shareholders. Cash flow per share of China Resources Pharmaceutical Group is HKD 0.50 per share, which is higher than the dividend per share paid by the company of HKD 0.11, so the company generates enough cash to maintain his dividend in the future.

The following figure shows payout ratios over earnings and cashflow of China Resources Pharmaceutical Group, compared againt world market average, China companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies. You might also need to check full financial report of China Resources Pharmaceutical Group.

China Resources Pharmaceutical Group payout

China Resources Pharmaceutical Group Stock performance

Finally, last moth China Resources Pharmaceutical Group showed a return of 10.00% compared to a worldwide -0.46% average, and a 3.00% of Health Care firms. Over the last year, the company obtained a 29.50% versus a worldwide performance of a 5.96%. More detailed information can be seen in the following graph for China and Pharmaceuticals and Biotechnology firms.

China Resources Pharmaceutical Group stock and market return

Next companies

China S Air Co H. China. Consumer Services.

China Shenhua Energy. China. Basic Materials.

China Shipping Dev H. China. Industrials.

China Shipping H. China. Industrials.

China South City Hol. China. Industrials.

China State Con (RC). China. Industrials.

Previous companies

China Resources Land. China. Financials.

China Resources Gas. China. Utilities.

China Resources Ceme. China. Industrials.

China Resources Beer. China. Industrials.

China Res Pwr Hdg RC. China. Utilities.

China Reinsurance (G. China. Financials.



All rights reserved

 information advertisement legal

Dividends Ranking | Firm Report | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Part of Enciclopedia Financiera Group

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.